An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma

NCT00787410 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

23

Enrollment

INDUSTRY

Sponsor class

Conditions

Mesothelioma

Interventions

DRUG: ZD1839

Sponsor

AstraZeneca